MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciad218

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023

Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial.

Hassanzadeh Hamid, Baber James, Begier Elizabeth, Noriega David C, Konishi Hiroaki, Yato Yoshiyuki, Wang Michael Y, Le Huec Jean Charles, Patel Vikas, Varga Peter, Liljenqvist Ulf, Conly John, Sabharwal Charu, Munjal Iona, Cooper David, Radley David, Jaques Anna, Patton Michael, Gruber William C, Jansen Kathrin U, Anderson Annaliesa S, Gurtman Alejandra, STaphylococcus aureus suRgical Inpatient Vaccine Efficacy Investigator Team

Рандомизированное исследованиеМногоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Staphylococcus aureus is a global pathogen that is frequently responsible for healthcare-associated infections, including surgical site infections (SSIs). Current infection prevention and control approaches may be limited, with S. aureus antibiotic resistance remaining problematic. Thus, a vaccine to prevent or reduce S. aureus infection is critically needed. We evaluated the efficacy and safety of an investigational 4-antigen S. aureus vaccine (SA4Ag) in adults undergoing elective open posterior spinal fusion procedures with multilevel instrumentation.

METHODS

In this multicenter, site-level, randomized, double-blind trial, patients aged 18-85 years received a single dose of SA4Ag or placebo 10-60 days before surgery. SA4Ag efficacy in preventing postoperative S. aureus bloodstream infection and/or deep incisional or organ/space SSIs was the primary end point. Safety evaluations included local reactions, systemic events, and adverse events (AEs). Immunogenicity and colonization were assessed.

RESULTS

Study enrollment was halted when a prespecified interim efficacy analysis met predefined futility criteria. SA4Ag showed no efficacy (0.0%) in preventing postoperative S. aureus infection (14 cases in each group through postoperative day 90), despite inducing robust functional immune responses to each antigen compared with placebo. Colonization rates across groups were similar through postoperative day 180. Local reactions and systemic events were mostly mild or moderate in severity, with AEs reported at similar frequencies across groups.

CONCLUSIONS

In patients undergoing elective spinal fusion surgical procedures, SA4Ag was safe and well tolerated but, despite eliciting substantial antibody responses that blocked key S. aureus virulence mechanisms, was not efficacious in preventing S. aureus infection. Clinical Trials Registration. NCT02388165.

Для цитирования: Hassanzadeh Hamid, Baber James, Begier Elizabeth, Noriega David C, Konishi Hiroaki, Yato Yoshiyuki, Wang Michael Y, Le Huec Jean Charles, Patel Vikas, Varga Peter, Liljenqvist Ulf, Conly John, Sabharwal Charu, Munjal Iona, Cooper David, Radley David, Jaques Anna, Patton Michael, Gruber William C, Jansen Kathrin U, Anderson Annaliesa S, Gurtman Alejandra, STaphylococcus aureus suRgical Inpatient Vaccine Efficacy Investigator Team. Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023. DOI: 10.1093/cid/ciad218.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.